



Autogenous Vaccines and Their Role in Animal Health Strategy

September 25-26, 2017

Het Pand

University of Ghent

Co-organized by IABS and Ghent University

The purpose of this conference is to start from an overview on the current situation and needs from the perspective of regulators, scientists, manufacturers and the end-user (veterinarians). The main focus will be on food producing animals, including fish. Further, proposals will be presented for a harmonized approach which will lead to a better understanding of the rationale for the intended use, better knowledge on the nature of isolates and improved production and quality of the final products. In addition, advanced techniques and methods will be presented and discussed to identify and propagate isolates, to upgrade production and to quickly estimate safety and even efficacy of autogenous vaccines by *in vitro* methods.

Recommendations will be drafted on how to improve the EU-legislation and communication between the EU-Member States on autogenous vaccines and on ways to increase transparency on quality and safety of the vaccines.

Scientific / Organizing Committee

Carmen	Jungbäck	IABS-EU
Joris	Vandeputte	IABS
Sven	Arnouts	University of Ghent - Provaxs
Peter	Schmid	IDT Biologika
Eric	Cox	University of Ghent – Provaxs
Sjaak	de Wit	Deventer
Vilma	Dosedlová	Institute for State Control of Veterinary Biologicals and Medicines

Day 1 – Monday, September 25, 2017

Afternoon

- Opening address - Prof. Frank Gasthuys, Dean, Faculty of Veterinary Medicine, University of Ghent, Belgium

Session 1

The role of autogenous vaccines

- Autogenous vaccines: Differences to minor markets/minor use(MUMS), emergency licensing , regular licensing - Dr. Carmen Jungbäck, IABS.EU
- When can autogenous vaccines replace or complement licensed vaccines: view of a manufacturer of autogenous and licensed vaccines - Dr. Peter Schmid, IDT Biologika
- Production and use of autogenous vaccines for pigs in Germany
- Practices and relevance for use of autogenous vaccines. Are “non-registered vaccines” proper alternatives?

Session 2

Current legal basis and proposals for update: regulators

- Situation in Belgium
- Situation in Czech Republic
- Situation in UK
- EU approach: CMDv/HMA
- US approach

Day 2 – Tuesday, September 26, 2017

Morning

Session 3

Current production: manufacturers and veterinarians, solutions for better vaccines

- Manufacturer autogenous
- Manufacturer autogenous, private laboratory - Sjaak de Wit, Deventer
- Manufacturer autogenous, stand alone manufacturer
- Manufacturer autogenous/regular
- Manufacturer autogenous: US approach on vector based vaccines
- Manufacturer regular
- Manufacturer regular
- Manufacturer academic
- Veterinarian Degudap (poultry)
- Veterinarian (fish) Xxxx, proposal Aqualife Services
- Development of new cell lines for the production of inactivated PRRSV autovaccines
- New adjuvants

Day 2 – September 26, 2017

Afternoon

Session 4

Updating legal basis

- Summary of the sessions and the discussions
- Position of the European Parliament
- Position of the European Commission
- Plenary / Panel discussion
- Conclusions and recommendations
- Closing remarks